Cannabis Campaigners' Guide News Database result:


After you have finished reading this article you can click here to go back.

UK: Cannabis conundrum

The Guardian

Tuesday 10 Jul 2001

---


What exactly is going on at GW Pharmaceutical, the Aim-listed producer
of high quality cannabis for medical purposes?

Just two weeks after its flotation Brian Whittle, the company's
scientific director, has acquired 50,000 shares at 127p each, increasing
his stake in GW to 11.97%.

Given that Mr Whittle's holding was reduced by 2% in the flotation, his
purchase appears, to say the least, strange.

That said, his dealings probably say more about the performance of GW
shares since their debut. Placed at 182p by broker Collins Stewart, they
have moved sharply lower - hit by, among other things, a report in the
British Medical Journal questioning whether cannabis was actually
effective in pain relief.

Again, this is surprising, because the float was around six times
oversubscribed. GW closed at 126.5p, down 19p, last night.


 

 

 

After you have finished reading this article you can click here to go back. 




This page was created by the Cannabis Campaigners' Guide.

Feel free to link to this page!